🎉 M&A multiples are live!
Check it out!

Piramal Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Piramal Pharma and similar public comparables like Syngene International, Suven Pharma, and Dishman Carbogen Amics.

Piramal Pharma Overview

About Piramal Pharma

Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.


Founded

2020

HQ

India
Employees

5.1K+

Website

piramal.com

Financials

LTM Revenue $1.1B

LTM EBITDA $173M

EV

$3.9B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Piramal Pharma Financials

Piramal Pharma has a last 12-month revenue of $1.1B and a last 12-month EBITDA of $173M.

In the most recent fiscal year, Piramal Pharma achieved revenue of $942M and an EBITDA of $159M.

Piramal Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Piramal Pharma valuation multiples based on analyst estimates

Piramal Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $817M $942M XXX XXX XXX
Gross Profit n/a $468M XXX XXX XXX
Gross Margin NaN% 50% XXX XXX XXX
EBITDA $104M $159M XXX XXX XXX
EBITDA Margin 13% 17% XXX XXX XXX
Net Profit $43.7M -$21.7M XXX XXX XXX
Net Margin 5% -2% XXX XXX XXX
Net Debt $118M $617M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Piramal Pharma Stock Performance

As of April 15, 2025, Piramal Pharma's stock price is INR 220 (or $3).

Piramal Pharma has current market cap of INR 290B (or $3.4B), and EV of INR 333B (or $3.9B).

See Piramal Pharma trading valuation data

Piramal Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$3.9B $3.4B XXX XXX XXX XXX $0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Piramal Pharma Valuation Multiples

As of April 15, 2025, Piramal Pharma has market cap of $3.4B and EV of $3.9B.

Piramal Pharma's trades at 3.6x LTM EV/Revenue multiple, and 22.4x LTM EBITDA.

Analysts estimate Piramal Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Piramal Pharma and 10K+ public comps

Piramal Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $3.9B XXX XXX XXX
EV/Revenue 3.7x XXX XXX XXX
EV/EBITDA 23.0x XXX XXX XXX
P/E 235.9x XXX XXX XXX
P/E/Growth 1.7x XXX XXX XXX
EV/FCF 117.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Piramal Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Piramal Pharma Valuation Multiples

Piramal Pharma's NTM/LTM revenue growth is 13%

Piramal Pharma's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, Piramal Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Piramal Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Piramal Pharma and other 10K+ public comps

Piramal Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 15% XXX XXX XXX XXX
EBITDA Margin 16% XXX XXX XXX XXX
EBITDA Growth 53% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 29% XXX XXX XXX XXX
Revenue per Employee $0.2M XXX XXX XXX XXX
Opex per Employee $0.1M XXX XXX XXX XXX
S&M Expenses to Revenue 4% XXX XXX XXX XXX
G&A Expenses to Revenue 3% XXX XXX XXX XXX
R&D Expenses to Revenue 1% XXX XXX XXX XXX
Opex to Revenue 54% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Piramal Pharma Public Comps

See public comps and valuation multiples for Contract Research & Manufacturing and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Jubilant Pharmova XXX XXX XXX XXX XXX XXX
Biocon XXX XXX XXX XXX XXX XXX
Syngene International XXX XXX XXX XXX XXX XXX
Dishman Carbogen Amics XXX XXX XXX XXX XXX XXX
Suven Pharma XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Piramal Pharma M&A and Investment Activity

Piramal Pharma acquired  XXX companies to date.

Last acquisition by Piramal Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Piramal Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Piramal Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Piramal Pharma

When was Piramal Pharma founded? Piramal Pharma was founded in 2020.
Where is Piramal Pharma headquartered? Piramal Pharma is headquartered in India.
How many employees does Piramal Pharma have? As of today, Piramal Pharma has 5.1K+ employees.
Who is the CEO of Piramal Pharma? Piramal Pharma's CEO is Mr. Peter DeYoung.
Is Piramal Pharma publicy listed? Yes, Piramal Pharma is a public company listed on BOM.
What is the stock symbol of Piramal Pharma? Piramal Pharma trades under 543635 ticker.
When did Piramal Pharma go public? Piramal Pharma went public in 2022.
Who are competitors of Piramal Pharma? Similar companies to Piramal Pharma include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics.
What is the current market cap of Piramal Pharma? Piramal Pharma's current market cap is $3.4B
What is the current revenue of Piramal Pharma? Piramal Pharma's last 12-month revenue is $1.1B.
What is the current EBITDA of Piramal Pharma? Piramal Pharma's last 12-month EBITDA is $173M.
What is the current EV/Revenue multiple of Piramal Pharma? Current revenue multiple of Piramal Pharma is 3.6x.
What is the current EV/EBITDA multiple of Piramal Pharma? Current EBITDA multiple of Piramal Pharma is 22.4x.
What is the current revenue growth of Piramal Pharma? Piramal Pharma revenue growth between 2023 and 2024 was 15%.
Is Piramal Pharma profitable? Yes, Piramal Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.